PBAC's latest decision on Sonidegib: Noted (2023). Considered for Treatment of metastatic or locally advanced basal cell carcinoma (BCC) in patients inappropriate for surgery and curative radiotherapy.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2017
Submissions
2
2017 → 2023
Eligible population
Patients with metastatic or locally advanced basal cell carcinoma who are inappropriate for surgery and curative radiotherapy due to the type, size, location, depth of penetration of the lesions and extent of the disease.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Comparator
vismodegib
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis only; no new ICER calculated in this submission (Category 3 submission regarding Risk Sharing Arrangement and pricing only).
Risk sharing
Risk-sharing arrangement in place — Continued Risk Sharing Arrangement (RSA) with subsidisation caps required. PBAC advised a one-off increase of 10% applied to the most recent Deed Year cap would be reasonable, maintaining the shared cap arrangement with vismodegib.
Submission history
Nov 2017: Recommended with restriction · Authority Required